Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,594,327
since: 14 May 2006

Antidepressant benefit may be apparent sooner

posted Tuesday, 18 July 2006

Timothy F. Kirn

TORONTO - Most clinical recommendations advise that patients who start an antidepressant be given 4-6 weeks to see whether they respond and have improvement.

But an analysis of more than 5,000 patients treated in clinical trials with a variety of antidepressants suggests that most patients who respond well start to improve within 2 weeks, Dr. Armin Szegedi said at the annual meeting of the American Psychiatric Association.

"This is a very strong, clinically relevant, and, perhaps to many, a surprising finding," said Dr. Szegedi, executive director of clinical projects, psychiatry, at Organon International Inc., Rosalind, N.J., in an interview.

The analysis included patients who were treated with six different, selective serotonin reuptake inhibitors, including paroxetine (Paxil) and fluoxetine; two tricyclic antidepressants, amitriptyline and doxepin; and venlafaxine (Effexor), a selective norepinephrine reuptake inhibitor.

More...

© 2006 Elsevier Inc. All rights reserved

tags:        

links: digg this    del.icio.us    technorati    reddit